Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice

References

• World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD). Available from: https://www.who.int/respiratory/copd/burden/en/. Accessed August 03, 2020.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2020 global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed August 03, 2020.
   Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2020 update). Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed February 02, 2021.
   Google Scholar
• EMA. Trimbow beclometasone/formoterol/glycopyrronium bromide; 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow. Accessed March 30, 2019.
   Google Scholar
• EMA. Trelegy Ellipta; 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta. Accessed March 30, 2019.
   Google Scholar
• FDA. Trelegy Ellipta (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg) Inhalation Powder; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209482s000lbl.pdf. Accessed March 30, 2019.
   Google Scholar
• Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med. 2018;142:73–80. doi:10.1016/j.rmed.2018.07.009
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Nakamura H, Takahashi S, et al.; Keio COPD Comorbidity Research (K-CCR) group. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:1053–1059. doi:10.2147/COPD.S79864
   PubMed Web of Science ®Google Scholar
• Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:781–792. doi:10.2147/COPD.S153655
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S91694
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al.; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012;141(1):81–86. doi:10.1378/chest.11-0038
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed summary of product characteristics; 2020. Available from: https://www.medicines.org.uk/emc/product/8666/smpc#gref. Accessed April 16, 2021.
   Google Scholar
• Chiesi Limited. Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution summary of product characteristics; 2021. Available from: https://www.medicines.org.uk/emc/medicine/33828#gref. Accessed April 16, 2021.
   Google Scholar
• Quint JK, Müllerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Goss H, Chandan J, Quint JK. P223 Validity and interpretation of spirometry for patients in primary care. Thorax. 2015;70(Suppl 3):A188–A190. doi:10.1136/thoraxjnl-2015-207770.359
   Web of Science ®Google Scholar
• Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172. doi:10.18553/jmcp.2018.24.11.1165
   PubMed Web of Science ®Google Scholar
• Moretz C, Sharpsten L, Bengtson LGS, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/COPD.S204649
   PubMed Web of Science ®Google Scholar
• Landis SH, Wurst K, Le HV, Bonar K, Punekar YS. Can assessment of disease burden prior to changes in initial COPD maintenance treatment provide insight into remaining unmet needs? A retrospective database study in UK primary care. COPD. 2017;14(1):80–85. doi:10.1080/15412555.2016.1240159
   PubMedGoogle Scholar
• Bogart M, Stanford RH, Lalibert F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S184653
   PubMed Web of Science ®Google Scholar
• Calabria S, Ronconi G, Dondi L, et al. Open triple therapy for chronic obstructive pulmonary disease: patterns of prescription, exacerbations and healthcare costs from a large Italian claims database. Pulm Pharmocol Ther. 2020;61:101904. doi:10.1016/j.pupt.2020.101904
   PubMed Web of Science ®Google Scholar
• Meeraus W, Wood R, Jakubanis R, et al. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. Int J Chron Obstruct Pulmon Dis. 2019;14:51–63. doi:10.2147/COPD.S181224
   PubMed Web of Science ®Google Scholar
• Bender BG, Vecino RA, McGrath K, Jones S. Comparative analysis of persistence to treatment among patients with asthma or COPD receiving AirFluSal Forspiro or Seretide Diskus salmeterol/fluticasone propionate combination therapy. J Allergy Clin Immunol Pract. 2016;4(5):884–889. doi:10.1016/j.jaip.2016.07.006
   PubMed Web of Science ®Google Scholar
• Kerwin E, Siler T, Tombs L, Sousa AR, Singletary K, Church A. Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients. Eur Respir J. 2015;46(suppl59):PA1490. doi:10.1183/13993003.congress-2015.PA1490
   Web of Science ®Google Scholar
• Lee SD, Xie CM, Yunus F, Itoh Y, Su R. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in Asian patients with severe chronic obstructive pulmonary disease [abstract]. Am Thorac Soc. 2014;A3768.
   Google Scholar
• Singh D, Corradi M, Spinola M, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J Chron Obstruct Pulmon Dis. 2017;12:2917–2928. doi:10.2147/COPD.S146822
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-4
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis. 2016;11:193–205. doi:10.2147/COPD.S95055
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respir Res. 2017;18(1):196. doi:10.1186/s12931-017-0683-x
   PubMedGoogle Scholar
• Buhl R, Criée CP, Kardos P, et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557–2568. doi:10.2147/COPD.S169958
   PubMed Web of Science ®Google Scholar
• Bloom CI, Douglas I, Usmani OS, Quint JK. Inhaled corticosteroid treatment regimens and health outcomes in a UK COPD population study. Int J Chron Obstruct Pulmon Dis. 2020;15:701–710. doi:10.2147/COPD.S241568
   PubMed Web of Science ®Google Scholar
• Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J. Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. J Manag Care Spec Pharm. 2020;17:1–13. doi:10.18553/jmcp.2020.20159
   Web of Science ®Google Scholar
• Dalon F, Roche N, Belhassen M, et al. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study. Int J Chron Obstruct Pulmon Dis. 2019;14:1839–1854. doi:10.2147/COPD.S214061
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell-Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA LABA for COPD: cohort study in real-world clinical practice. Chest. 2020;157(4):846–855. doi:10.1016/j.chest.2019.11.007
   PubMed Web of Science ®Google Scholar
• Ferroni E, Belleudi V, Sascini S, et al.; OUTPUL Study Group. Role of tiotropium in reducing exacerbations of chronic obstructive pulmonary disease when combined with long‐acting β2‐agonists and inhaled corticosteroids: the OUTPUL study. J Clin Pharmacol. 2016;56(11):1423–1432. doi:10.1002/jcph.750.
   PubMed Web of Science ®Google Scholar
• Voorham J, Corradi M, Papi A, et al. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res. 2019;5(3):00106–2019. doi:10.1183/23120541.00106-2019
   PubMedGoogle Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75–80. doi:10.1080/02770900500448738
   PubMed Web of Science ®Google Scholar